Richter Gedeon Nyrt./FtRICHTER
07:00
09:00
11:00
13:00
15:00
1D1W1MYTD1Y5YMAX
About Richter Gedeon Nyrt.
Ticker
FtRICHTER
Sector
Primary listing
BUX
Employees
10,943
Headquarters
Budapest, Hungary
Website
RICHTER Metrics
BasicAdvanced
Ft 1.81T
8.28
Ft 1,207.56
0.31
Ft 508.56
5.09%
Price and volume
Market cap
Ft 1.81T
Beta
0.31
52-week high
Ft 10,730
52-week low
Ft 9,790
Dividend rate
Ft 508.56
Financial strength
Current ratio
3.926
Quick ratio
2.364
Long term debt to equity
6.693
Total debt to equity
7.356
Dividend payout ratio (TTM)
42.08%
Interest coverage (TTM)
25.42%
Profitability
EBITDA (TTM)
305,420.6
Gross margin (TTM)
68.03%
Net profit margin (TTM)
24.46%
Operating margin (TTM)
28.35%
Effective tax rate (TTM)
18.06%
Revenue per employee (TTM)
Ft 82,550,000
Management effectiveness
Return on assets (TTM)
10.59%
Return on equity (TTM)
17.84%
Valuation
Price to earnings (TTM)
8.281
Price to revenue (TTM)
2.026
Price to book
1.4
Price to tangible book (TTM)
1.87
Price to free cash flow (TTM)
8.561
Free cash flow yield (TTM)
11.68%
Free cash flow per share (TTM)
1,168.146
Dividend yield (TTM)
5.09%
Forward dividend yield
5.09%
Growth
Revenue change (TTM)
11.33%
Earnings per share change (TTM)
-3.42%
3-year revenue growth (CAGR)
9.15%
10-year revenue growth (CAGR)
9.55%
3-year earnings per share growth (CAGR)
4.25%
10-year earnings per share growth (CAGR)
18.92%
What the Analysts think about RICHTER
Analyst ratings (Buy, Hold, Sell) for Richter Gedeon Nyrt. stock.
Bulls say / Bears say
Richter’s flagship antipsychotic Vraylar generated HUF 229 billion in royalties for 2024, up 18% year-on-year, and will remain exempt from proposed U.S. pharmaceutical tariffs, safeguarding its revenue stream in the key U.S. market. (Reuters)
Gedeon Richter submitted a biosimilar version of Roche’s RoActemra (tocilizumab) to the European Medicines Agency in March 2025, positioning its Biotech unit for profitability with an anticipated 2026 launch. (Reuters)
In mid-2025, the U.S. FDA approved the expanded use of Vraylar (cariprazine) for bipolar depression, broadening its label and underpinning future royalty growth in the U.S. market. (Bloomberg)
Data summarised monthly by Lightyear AI. Last updated on 22 Sept 2025.
RICHTER Financial Performance
Revenues and expenses
RICHTER Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Richter Gedeon Nyrt. stock?
Richter Gedeon Nyrt. (RICHTER) has a market cap of Ft1.8T as of September 25, 2025.
What is the P/E ratio for Richter Gedeon Nyrt. stock?
The price to earnings (P/E) ratio for Richter Gedeon Nyrt. (RICHTER) stock is 8.28 as of September 25, 2025.
Does Richter Gedeon Nyrt. stock pay dividends?
Yes, the Richter Gedeon Nyrt. (RICHTER) stock pays dividends to shareholders. As of September 25, 2025, the dividend rate is Ft508.5635 and the yield is 5.09%. Richter Gedeon Nyrt. has a payout ratio of 42.08% on a trailing twelve-month basis.
When is the next Richter Gedeon Nyrt. dividend payment date?
The next Richter Gedeon Nyrt. (RICHTER) dividend payment date is unconfirmed.
What is the beta indicator for Richter Gedeon Nyrt.?
Richter Gedeon Nyrt. (RICHTER) has a beta rating of 0.31. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.